Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- ACCEL Lite: VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or StrokeIn this interview, Nanette Kass Wenger MD, MACC and Erin A. Bohula, MD, FACC discuss the VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke.
- CORALreef Lipids: Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in High-Risk PatientsEnlicitide decanoate, an oral PCSK9 inhibitor, significantly reduced LDL-C levels in patients with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event, according to results of the CORALreef Lipids trial published Feb. 4 in the NEJM.
- To β or Not to β? Insights From the BETAMI-DANBLOCK TrialThe BETAMI-DANBLOCK (Beta-Blockers after Myocardial Infarction in Patients without Heart Failure) trial results demonstrated that, in patients with recent type 1 or type 2 myocardial infarction (MI) and left ventricular ejection fraction (LVEF) ≥40%...
- Noninvasive Predictors of LA Compliance Post TMVTIn patients with severe mitral regurgitation (MR), low left atrial (LA) reservoir strain (LASr) and prior atrial fibrillation (AFib) intervention or LA appendage (LAA) ligation may predict low invasive LA compliance and limited V-wave reduction after transcatheter mitral valve therapy (TMVT)...
- EMPHASIS: Minocycline Initiation Effective, Safe Within 72 Hours of Acute Ischemic StrokeInitiation of the multi-target anti-neuroinflammatory drug minocycline within 72 hours of acute ischemic stroke had a significant benefit in functional outcome compared to placebo, with no increased safety risks, according to findings from the EMPHASIS trial published Jan. 30 in The Lancet.